SanofiXSWX:SAN 87 5-Year Yield-on-Cost % is 0.00 as of Jun. 27, 2026. GuruFocus rates XSWX:SAN with a GF Score™ of 87/100 and a GF Value™ of CHF104.30. The stock has 2 warning signs investors should review. Among 516 Drug Manufacturers companies, Sanofi ranks better than 82.75% on this metric.
Sanofi's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Sanofi's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Sanofi's highest Yield on Cost was 7.07. The lowest was 3.89. And the median was 4.79.
XSWX:SAN's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.43 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sanofi 5-Year Yield-on-Cost % Related Terms
XSWX:SAN vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Sanofi's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sanofi's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Sanofi is calculated as
Sanofi (XSWX:SAN) has a 5-Year Yield-on-Cost % of 0.00 as of Jun. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sanofi and its competitors. Over the past decade, Sanofi's 5-Year Yield-on-Cost % has ranged from 3.89 to 7.07. According to the industry distribution chart, Sanofi ranks #89 out of 516 companies in the Drug Manufacturers industry, placing it in the top 17.2%.
Is Sanofi's 5-Year Yield-on-Cost % too high?
Sanofi's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 3.89 to a high of 7.07. Based on the distribution chart, Sanofi ranks #89 out of 516 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #89 out of 516 companies for 5-Year Yield-on-Cost %. This places Sanofi in the top 17% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.43. Historically, Sanofi's own 5-Year Yield-on-Cost % has ranged from 3.89 to 7.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.43, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is CHF104.30, compared to a current price of CHF73.20 — trading 29.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current 5-Year Yield-on-Cost % is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (XSWX:SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.
Key valuation signals for XSWX:SAN:
5-Year Yield-on-Cost %: 0.00
GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score
Get the complete analysis for XSWX:SAN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SAN has been successfully added to your 